Global epidemiology of valvular heart disease
Global epidemiology of valvular heart disease Valvular heart disease (VHD) encompasses a range of disorders affecting the valves of the heart, including the mitral, aortic, tricuspid, and pulmonic valves. Globally, VHD represents a significant public health concern due to its impact on morbidity and mortality, especially among aging populations. Its epidemiology varies considerably across different regions, influenced by socioeconomic factors, healthcare infrastructure, and prevalent disease etiologies.
Global epidemiology of valvular heart disease In high-income countries, degenerative calcific aortic stenosis and mitral regurgitation are the predominant forms of VHD, largely attributable to aging populations. Advances in healthcare have led to increased longevity, which paradoxically results in a higher burden of age-related valvular degenerative changes. The increasing prevalence of conditions such as hypertension and hyperlipidemia further exacerbates this trend. Conversely, rheumatic heart disease (RHD) remains a leading cause of VHD in low- and middle-income countries, particularly in sub-Saharan Africa, South Asia, and parts of Southeast Asia. RHD predominantly affects children and young adults, often resulting from recurrent streptococcal infections that lead to rheumatic fever and subsequent valve damage.
The epidemiology of VHD is also shaped by infectious and congenital causes. Congenital valve anomalies, such as bicuspid aortic valves, are more common in certain populations and can lead to early valve dysfunction requiring intervention. Additionally, infectious endocarditis, although less common, can cause acute valvular destruction, especially in regions with a high prevalence of rheumatic fever or intravenous drug use. Global epidemiology of valvular heart disease
Global epidemiology of valvular heart disease In terms of disease burden, epidemiological studies reveal that VHD accounts for a significant proportion of cardiovascular hospitalizations worldwide. The Global Burden of Disease Study highlights that the prevalence of moderate to severe VHD is increasing, with estimates suggesting that millions are affected globally. The disease’s impact is compounded by limited access to diagnostic tools like echocardiography in resource-constrained settings, leading to underdiagnosis and delayed treatment.
Global epidemiology of valvular heart disease Treatment strategies for VHD vary based on severity, etiology, and patient comorbidities. Surgical valve repair or replacement remains the cornerstone of management, with transcatheter interventions gaining prominence, especially in high-risk surgical candidates. However, disparities in healthcare access significantly influence outcomes. Developed countries benefit from advanced surgical and catheter-based technologies, whereas many low-income regions struggle with capacity and infrastructure limitations.
Prevention efforts are crucial, especially in addressing rheumatic fever through improved hygiene, prompt treatment of streptococcal infections, and public health initiatives. Screening programs and early diagnosis can mitigate disease progression and reduce the need for invasive procedures. Additionally, ongoing research into minimally invasive therapies and tissue-engineered valves promises to transform the future landscape of VHD management.
Understanding the global epidemiology of valvular heart disease underscores the importance of tailored public health strategies, equitable resource distribution, and continued innovation in diagnosis and treatment. Addressing these challenges is essential to reduce the worldwide burden of VHD and improve patient outcomes across different socioeconomic settings. Global epidemiology of valvular heart disease